To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients

A Research Study to Describe the Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS). An Assessment of Two Case Studies

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01755429

Enrollment

Registered

2012-12-24

Start date

2012-05-31

Completion date

2012-07-31

Last updated

2012-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

Brief summary

This protocol is intended to formally collect data on the treatment of aHUS with eculizumab in Japanese patients.

Interventions

None listed

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Patient and/or legal guardian must be willing and able to give written informed consent and id the patient is not an adult and able to read and write, the patient is willing to give written informed assent 2. Eculizumab treatment initiated as personal importation for aHUS in 201

Exclusion criteria

Not Applicable

Design outcomes

Primary

Measure	Time frame
Change in platelet count from baseline	26 weeks

Countries

Japan

Outcome results